A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD  by Hutchinson, Anastasia F. et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 2472–24810954-6111/$ - see fr
doi:10.1016/j.rmed.
Corresponding au
fax: +61 03 9342 849
E-mail address: AA community-based, time-matched, case-control
study of respiratory viruses and exacerbations
of COPD
Anastasia F. Hutchinsona,b,c,, Anil K. Ghimirea, Michelle A. Thompsona,d,
Jim F. Blackc, Caroline A. Brandb, Adrian J. Loweb, David M. Smallwooda,
Ross Vlahosd, Steven Bozinovskid, Graham V. Brownc,
Gary P. Andersond, Louis B. IrvingaaDepartment of Respiratory Medicine, Melbourne Health, Victoria 3050, Australia
bDepartment of Clinical Epidemiology and Health Services Evaluation Unit, Melbourne Health, Victoria 3050, Australia
cVictorian Infectious Diseases Service, Melbourne Health, & NHMRC Centre for Clinical Research Excellence in Infectious
Diseases, University of Melbourne, Victoria 3010, Australia
dDepartments of Medicine and Pharmacology Cooperative Research Centre for Chronic Inflammatory Diseases,
University of Melbourne, Parkville, Victoria 3010, Australia
Received 26 April 2007; accepted 16 July 2007
Available online 5 September 2007KEYWORDS
Lung diseases:
obstructive;
Respiratory tract
infections;
Respiratory virusesont matter & 2007
2007.07.015
thor. Department
3.
nastasia.HutchinsSummary
Respiratory viruses are associated with severe acute exacerbations of chronic obstructive
pulmonary disease (COPD) in hospitalized patients. However, exacerbations are increas-
ingly managed in the community, where the role of viruses is unclear. In community
exacerbations, the causal association between viruses and exacerbation maybe con-
founded by random fluctuations in the prevalence of circulating respiratory viruses.
Therefore, to determine whether viral respiratory tract infections are causally associated
with community exacerbations, a time-matched case-control study was performed.
Ninety-two subjects (mean age 72 yrs), with moderate to severe COPD, (mean FEV1 40%
predicted), were enrolled. Nasopharyngeal swabs for viral multiplex polymerase chain
reaction and atypical pneumonia serology were obtained at exacerbation onset. Control
samples were collected in synchrony, from a randomly selected stable patient drawn from
the same cohort.
In 99 weeks of surveillance, there were 148 exacerbations. Odds of viral isolation were 11
times higher in cases, than their time-matched controls (34 discordant case-control pairs;
in 31 pairs only the case had virus and in three pairs only control). Picornavirus (26),Elsevier Ltd. All rights reserved.
of Respiratory Medicine, Melbourne Health, Victoria 3050, Australia. Tel.: +61 03 9342 8772;
on@mh.org.au (A.F. Hutchinson).
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A case-control study of viruses in COPD 2473influenza A (3), parainfluenza 1,2,3 (2), respiratory syncytial virus (1), and adenovirus (1)
were detected in cases while adenovirus (1) and picornavirus (2) were detected in
controls. In patients with moderate or severe COPD the presence of a virus in upper airway
secretions is strongly associated with the development of COPD exacerbations. These data
support the causative role of viruses in triggering COPD exacerbations in the community.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Patients with chronic obstructive pulmonary disease (COPD),
particularly those with moderate or severe disease (GOLD
stage 2+illness), often experience frequent debilitating
exacerbations during the course of their disease.1 From
the patient’s perspective, acute exacerbations of COPD
(AECOPD) result in acute ill health and reduced quality of
life, especially the ability to perform normal activities2 and
can contribute to accelerated decline in lung function and
loss of lean muscle mass.3,4 AECOPD are also a major burden
on the health care system, especially during the winter
season.5 As much of the cost of AECOPD stems from
hospitalization,6,7 and hospitalization increases the risk of
complications, there is increasing interest in the community
management of this disease to optimize outcomes and
minimize costly admissions.
It is believed that the majority of AECOPD are caused by
respiratory infections8 although exposure to respirable
particulates in polluted air,9 pulmonary thromboembolism10
and other, unknown causes are also implicated. Viral
respiratory infection is strongly suspected to cause AECOPD.
Previous longitudinal, community-based and hospitalization
studies have found that viral infections are common
(39–56%) in patients with AECOPD11,12 and are most usually
associated with severe presentations. Most recently, Papi
and colleagues have demonstrated the association of proven
viral infection with worsening of cellular and biochemical
indices of inflammation.13 While these studies do not
formally exclude bystander effects, they provide very strong
evidence that viral respiratory infection is an important
cause of severe AECOPD requiring hospitalization and
suggest that viral infection is a cause of AECOPD in the
community. In contrast, Hurst and colleagues recently
studied common cold, assessed by coryzal symptoms, and
AECOPD frequencies in the community, by comparing diary
cards with spirometry.14 They concluded that exacerbation
frequency is associated with an increased symptomatic cold
frequency. This study does not, however, control for other
causes of coryzal symptoms such as allergic rhinitis that are
prevalent in the Australian context. As there may be
regional differences in the type of viruses circulating
through a community, it was relevant to explore the
spectrum of respiratory viruses associated with AECOPD in
an Australian community cohort.
To address this limitation in our understanding, we have
established a long-term longitudinal cohort in Melbourne,
that allows rigorous case control methodology, to address
whether respiratory viruses are important causes of com-
munity AECOPD. This paper addresses the research question;
is isolation of a respiratory virus more strongly associated
with AECOPD than stable disease, in community-dwellingpatients chosen at the same time, from the same COPD
cohort. A particular advantage of the time-matched case-
control method, where cases (AECOPD) are matched with
controls at the time of exposure, is that it can accommodate
fluctuations in the type, virulence and prevalence of
respiratory viruses passing through the community.
Our data demonstrate that viruses are a major cause of
AECOPD, but also that virally mediated AECOPD are not
invariably severe enough to warrant hospitalization. Our
data may therefore contribute to understanding the natural
history of COPD and optimizing patient care in community
health networks.
Methods
The study, designated the Melbourne Longitudinal COPD
Cohort study, has been established as an open cohort of
participants with COPD to investigate the aetiology and
pathophysiology of COPD and its exacerbations.
Participants
Figure 1 summarizes recruitment to the cohort in
2003–2005. Inclusion criteria were diagnosis of COPD
according to GOLD criteria stage II–IV, smoking history of
greater than or equal to 10 pack-years, at least one
inpatient admission with an exacerbation of COPD in the
past 24 months, age less than 85 years and willingness to
give informed consent. Patient characteristics are shown in
Table 1. Exclusion criteria were living more than 50 km from
the hospital, predominant asthma (FEV1 reversibility X15%
on spirometry),15,16 lung cancer, a primary diagnosis of
bronchiectasis or idiopathic pulmonary fibrosis, chronic
systemic inflammatory conditions such as rheumatoid
arthritis, renal failure requiring dialysis and patients
identified as requiring palliative care. The Human Research
Ethics Committee (HREC) of Melbourne Health approved the
study and written informed consent was obtained from all
subjects.
Study design
The study design was a time-matched case control study in
which an individual with an exacerbation was matched with
a control randomly selected from within the cohort who was
not exacerbating at that time. The study was powered to
assess the primary outcome of association of viral respira-
tory infection with AECOPD.
COPD exacerbations were defined by the Anthonisen
criteria17: Type I as an increase in dyspnoea, sputum volume
and sputum purulence for more than 24 h, Type II as any two
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Patients Enrolled in COPD Cohort  N =92  (2003 to 2005)
Total AECOPD over the follow-up period from 2003-2005
N = 159 AECOPD
Number of AECOPD per patient
0        AECOPD = 32 (35%)
1 to 2 AECOPD = 36 (40%)
3 to 4 AECOPD = 15 (16%)
5 to 6 AECOPD =   6   (6%)
7 to 8 AECOPD =   3   (3%)
AECOPD
Included in Case-Control Analysis N = 148
Excluded AECOPD (N = 11)
Aspiration Pneumonia     = 1
Missed = 7
No control obtained = 3
Person Weeks of Follow-up
Median = 47 weeks per patient
(Range 1-99 weeks per patient)
Reasons for withdrawal during follow-up. (N= 35)
Participated in 2003 only                     =  15
Died =    7
Deterioration in co morbid disease      =    5
Moved > 50 kms                                  =    2
Clinical Trial Participation                   =   2
Figure 1 Melbourne Longitudinal COPD Cohort: patients and COPD exacerbations included in this study.
A.F. Hutchinson et al.2474of the above symptoms and Type III as one of the above
symptoms accompanied by sore throat and nasal discharge
within 5 days, fever without other cause, increased cough
and an increase in respiratory rate or heart rate 20% above
baseline values.18 Severity of exacerbations was defined
according to the Burge and Wedzicha18 consensus report
(2003). At resolution, the exacerbation severity was coded
as the maximum severity of each episode according to the
consensus criteria.18 Stable COPD was defined as no
requirement for increased treatment above maintenance
therapy (other than bronchodilators) for 30 days.Identification of exacerbations
Identification of exacerbations at an early stage was
achieved by use of individualised patient action plans that
included information about symptoms and instructions to
contact the study team when key symptoms developed
(increased dyspnoea, increased wheeze, decreased exercise
tolerance, increased cough or change in sputum colour,
rhinorrhoea, nasal congestion, sore throat, myalgia or
headaches, fever and or chills). This was further reinforced
by fortnightly phone contact. Resolution of an exacerbation
was defined as completion of treatment with antibiotics and
increased steroids, and return of symptoms to baseline
levels for 48 h. If symptoms had not fully resolved within 30
days of exacerbation onset, symptoms needed to be stable
for 48 h and not require further acute treatment. A missedexacerbation was defined as symptoms not reported within 7
days of onset.
Data and sample collection
At baseline, demographic data, spirometry, carbon mon-
oxide diffusing capacity (DLCO), 6-min walk test,19 MRC
Dyspnoea Scale,20 St. George Respiratory Questionnaire and
clinical examination data were obtained. The BODE Index21
at recruitment was calculated. Baseline pathology samples
consisted of nose and throat swabs for respiratory virus
multiplex PCR, atypical pneumonia serology, sputum (if
available) for bacterial culture and serum for measurement
of inflammatory indices (differential white cell count
(WCC), erythrocyte sedimentation rate (ESR), and C-
reactive protein (CRP)).
Cases
During exacerbations nose and throat swabs were collected
on the day of identification and again 5–7 days later.
Respiratory multiplex PCR was repeated at day 30–60 once
the exacerbation had resolved.
Controls
Identical respiratory PCR samples were obtained from
controls within 5 days of the identification of the case.
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Table 1 Baseline characteristics of the patients.
N. 92
Age 72 yrs (49–85 yrs)
Sex Male: Female M 63% F 37%
FEV1 (L)
 0.93 (L) (0.35–1.91L)
% Pred. 40% (12–69%)
FVC (L) 2.07 (L) (0.78–3.90L)
% Pred. 66% (21–100%)
FEV1/FVC Ratio
 45% (23–70%)
DLCO* (N ¼ 65) 7.8 (3.4–28.1),
% Pred. 31% (1–105%)
KCO 1.85 (0.4–4.8),
% Pred. 44% (9–112%)
White cell count 8.8 109/L (5–18.3)
ESR 19.1mm/1 h (1–77)
C-reactive protein 6.4mg/L (o2–42)
Hypercapnoea 17%
Pack years smoking 53 (10–160)
Current smoker 22%
Chronic bronchitisy 82%
Domiciliary Oxygen 29%
BODE Index21/GOLD GOLD 2 N ¼ 19 BODE 3.89 (1–8)
GOLD 3 N ¼ 33 BODE 6.39 (4–10)
GOLD 4 N ¼ 40 BODE 7.93 (4–10)
Influenza vaccination 87%
Living situation Alone 29%
With spouse 47%
With family 21%
Other 3%
Abbreviations: (FEV1) forced expiratory volume in 1 s, (FVC
(L) forced viral capacity in litres, (DLCO) diffusion lung carbon
monoxide, KCO ¼ (DLCO/unit alveolar volume), % Pred.,
percent of normal age adjusted predicted values; ESR,
erythrocyte sedimentation rate.
Data expressed as mean (range). Rest as number and
percentage of the cohort.
yClinical definition of productive sputum for more than
three months at the time of enrolment.
A case-control study of viruses in COPD 2475The controls were identified from within the cohort using
computer generated random number selection from among
the currently stable COPD patients, who did not carry the
same virus as the case at recruitment.Pathogen detection
Respiratory virus multiplex PCR and atypical pneumonia
serology were performed at the Victorian Infectious Disease
Reference Laboratory (VIDRL, a WHO virology reference
laboratory).22 The following viruses were screened; influen-
za A and B, picornavirus, respiratory syncytial virus (RSV),
parainfluenza and adenovirus. Previous studies conducted by
VIDRL have established that the multiplex PCR has high
sensitivity and specificity for detection of these viruses.22
Blood for atypical pneumonia serology was obtained on
day one and thirty of each exacerbation and screened for
Influenza A and B, Chlamydia pneumoniae and C. psittaci,
Legionella pneumophila and Mycoplasma pneumoniae. Anexacerbation associated with an atypical pathogen was
defined as at least a four-fold rise in serum antibody titre
between the day one and day thirty specimens. Atypical
serology was performed by VIDRL Serology Laboratory, using
the following assays; Legionella spp. using an in-house
indirect fluorescence antibody (IFA) assay developed accord-
ing to standard procedures,23 Chlamydia spp. specific serum
IgG antibodies were detected using SeroELISATM Chlamydia-
IgG Enzyme-linked Immunosorbent Assay (ELISA), and
C. pneumoniae, C. trachomatis and C. psittaci were
identified using Chlamydia IgG SeroFIATM’ IFA test kits
(Savyon Diagnostics Ltd, Ashdod, Israel). M. pneumoniae
was detected using SERODIAs-MYCO 11 particle agglutina-
tion test (Fujirebio Inc. Tokyo Japan), and IgM antibodies
were detected by ELISA using SeroMPTM (Savyon Diagnostics
Ltd). Influenza A and B antibodies were detected using an in-
house complement fixation antibody test developed by
VIDRL Serology Laboratory, in accordance with standard
diagnostic methods.24
Spontaneously expectorated sputum samples were ob-
tained on day 1–5 after onset of AECOPD. Respiratory
bacteria were identified by sputum microscopy and culture
performed by Melbourne Pathology according to standard
clinical laboratory procedures. Bacterial load was deter-
mined using semi-quantitative methods.
Measurement of inflammatory serum markers
Measurement of the WCC, ESR and CRP were performed by
the clinical pathology service. Serum CRP was performed by
Melbourne Pathology, using an automated spectrometer
(Olympus AU2700) and Olympus immuno-turbidimetric test,
manufactured by Olympus Diagnostica GmbH (Irish Branch).
Limits of detection were 2–300mg/L, and values4300mg/L
were obtained by automated onboard dilution.
Measurement of symptoms
Severity of respiratory symptoms was scored using the MRC
dyspnoea scale,20 the Borg dyspnoea score when performing
routine daily activities25 and the Symptom Severity Index.26
AECOPD were confirmed by calculating the change in
symptom severity from patients’ own stable baseline values.
A score for the presence of viral symptoms was calculated on
day 1 and 5 of each AECOPD. This measured the following
symptoms; rhinorrhoea, nasal congestion, sore throat,
myalgia or headaches, and subjective fever, chills or rigors.
Each symptom was recorded on a scale of zero (absent
symptom) to three (severe).27–33
Statistical analysis
Viral infection was defined as a respiratory virus identified
on day one and/or day five by respiratory PCR of nose and
throat swabs. To determine whether a virus was more likely
to be associated with an exacerbation (Case) or stable COPD
(Control), a matched pair analysis of case-control pairs was
performed and an odds ratio with 95% confidence interval
was calculated (Table 2). McNamara’s chi square test for
paired samples was used to measure the significance of the
association.
ARTICLE IN PRESS
Table 2 Time-matched case-control analysis for infec-
tion with respiratory viruses.
Controls
PCR
Positive Negative
Cases
PCR positive 0 33
PCR negative 3 112
Cases were patients suffering from AECOPD. Controls were
time matched clinically stable patients drawn randomly from
the same cohort. Positive means a respiratory virus was
detected and negative means no virus was detected. The
odds ratio for detection of a virus during AECOPD was 11 [95%
CI; 3.45–56.07], (po0.001).
A.F. Hutchinson et al.2476Paired conditional logistic regression was performed to
test whether the odds of virus detection was equivalent in
case and controls. Potential predictors tested using uni-
variate analysis were; age, sex, smoking status, disease
severity, COPD sub-type and functional status (measured by
BODE Index).21 Cluster analysis was used to adjust for
repeated AECOPD from the same individual—this technique
adjusts the standard error around the estimate of associa-
tion between predictor and the outcome in question. The
sensitivity and specificity of viral symptom scores as
predictors of PCR positivity were calculated using standard
methodology.34
To account for varying periods of follow-up, person-weeks
of observation were calculated for the surveillance periods
in 2003 and 2004–2005. The incidence of atypical pneumonia
infections was calculated as incidence per time at risk
(incidence density). The total person-weeks of observation,
minus the time in which participants had exacerbations
associated with atypical organisms, was used as the
denominator. The incidence density of atypical organisms
is reported as incidence per 1000 person-weeks of observa-
tion.
Measurements of inflammatory indices were right skewed
and were log-transformed prior to further analysis, (chi
square tests were used to test the distribution was normal).
To test whether there was an acute change in levels of
inflammatory indices (CRP, ESR) at AECOPD onset, inflam-
matory indices were compared between stable baseline and
AECOPD onset using paired t-tests. Results are presented as
the geometric mean ratio of AECOPD onset to stable
baseline values.
All analyses were performed using STATA Version 8.2.35Results
Patients
Characteristics of the study participants are shown in
Table 1, (additional baseline data Supplementary Table 3).
Twenty-nine percent were on long-term home oxygen. Mean
pack years of smoking were 45 (Range 10–160) and 22% of
patients were current smokers. Eighty-seven percent hadreceived annual influenza vaccination for several years and
were current for the multivalent pneumococcal vaccine.
Twenty-eight (30%) patients who were colonized with
potentially pathogenic bacteria and had frequent AECOPD
(greater than 2.5 per year) were referred for diagnostic High
Resolution Computerized Tomography Scan (HRCT), changes
consistent with bronchiectasis were identified in 13.
Exacerbations
Patients were monitored over 3 years; from July to
December 2003 (Winter–Spring) and from August 2004 to
December 2005. The total number of person-weeks of
observation was 4289. The median number of weeks of
monitoring was 47 weeks per patient (range 1–99 weeks).
There were 148 exacerbations; 63% patients had at least one
exacerbation and 44% had more than one exacerbation
(range 2–6 exacerbations). The mean number of exacerba-
tions per patient per month was 0.14 and exacerbations per
patient per year 1.68. Time from symptom onset to sampling
was short (mean 2.4 days). Sixty-four percent of patients
with exacerbations contacted the study staff, while the rest
were identified on routine fortnightly phone call. Thirty-
eight percent of AECOPD were mild, 43% moderate and 19%
severe.18 Eighty percent of AECOPD were treated in the
community with oral antibiotics and/or oral corticosteroids.
Table 3 summarises details of exacerbation type and
severity.
Viruses at baseline
Adenovirus and RSV were detected by respiratory PCR from
two patients at baseline. They did not report any symptoms
of viral upper respiratory tract infection. All subsequent
tests on these patients were negative.
Viruses during AECOPD
There was a total of thirty-three viruses detected by
respiratory PCR at the onset of AECOPD; influenza A (3),
picornavirus (26), parainfluenza 1, 2, or 3 (2), RSV (1) and
adenovirus (1). Twenty-eight (84%) of viruses were detected
on day 1 after symptom onset and an additional five
picornaviruses were detected at day 5 after onset in
patients who remained symptomatic. At the day 30 follow-
up one patient remained colonised with picornavirus when
stable.
Three time-matched controls had viruses detected;
picornavirus (2) and adenovirus (1) although these patients
had no symptoms other than slight nasal congestion or
rhinorrhoea. Respiratory viruses detected on day 1–5 of
exacerbations in both cases and controls were included in
the case-control analysis. There were 34 discordant pairs
from 148 case-control pairs. The odds ratio was 11 (95%CI;
3.45–56.07, po0.001). In 33 pairs the case was positive for
virus and the control was negative and in three pairs the
control had virus while the case had no virus. Results for the
case control analysis are summarized in Table 2.
Paired conditional logistic regression demonstrated that
none of the following were predictors of viral detection;
age (p ¼ 0.287), gender (p ¼ 0.578), living situation
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Table 3 Characteristics of exacerbations.
Total exacerbations 148
Mean time to sampling 2.4 days (1–12 days)
Exacerbations reported by
patients
64%
Pathogens detected
Only virus 21
Only bacteria 30
Co-infection 12
Atypical organism 3
Virus detected in cases
Influenza A 3
Rhinovirus 26
Adenovirus 1
Parainfluenza 1,2,3 2
RSV 1
Bacteria detected in cases at onset
Hemophilus influenzae 16
Pseudomonas spp. 9
Streptococcus pneumoniae 7
Moraxella catarrhalis 3
Staphylococcus aureus 3
Stentrophomonas maltophilia 3
Other Gram negatives 8
Atypical organisms on serology
Chlamydia pneumoniae 1
Chlamydia psittaci 1
Mycoplasma pneumoniae 1
Severity of exacerbations
Mild 38%
Moderate 43%
Severe 17%
Life-threatening 2%
Anthonisen type17
Type I 33%
Type II 16%
Type III 51%
Burge and Wedzicha Consensus Report.18
A case-control study of viruses in COPD 2477(p ¼ 0.328), current smoker or not (p ¼ 0.165), diagnosis of
chronic bronchitis (p ¼ 0.544) or childhood asthma
(p ¼ 0.277). On the other hand, less severe disease
(measured by FEV1% predicted) was predictive of viral
isolation. The odds of having a positive viral PCR increased
by 6% for each 1-unit improvement in FEV1% predicted (OR
1.06, [95%CI 1.03–1.09], po0.001). Functional status was
also predictive PCR positivity with a 34% decrease in the
odds of having a positive viral PCR per 1-unit increase in the
BODE Index (OR 0.66, [95% CI 0.54–0.80], po0.001). All the
above predictors were analysed using univariate regression
models.Contact patterns with children
Twenty-eight patients (30%) had AECOPD of viral aetiology
confirmed by respiratory PCR. Eight patients (32%) of the
cohort had regular contact (3–7 days per week) with infantsor children less than 10 years of age. Seven (88%) of these
patients had at least one PCR positive AECOPD. There were
four patients who had multiple viral AECOPD confirmed by
PCR, three of the four (75%) had regular contact with
children.
Association between viral symptoms and rates
of viral detection
A virus was identified on respiratory PCR in 21.0% of
exacerbations overall and 31% of cases with three or more
viral symptoms and an overall score of X4. The individual
symptoms with the highest predictive values were the
presence of rhinorrhoea (Odds ratio [OR] 4.86, [95%CI:
1.82–14.31], p ¼ 0.004), and sore throat (OR 2.24, [95%CI:
0.93–5.55], p ¼ 0.05). Other symptoms associated with viral
infection were not statistically significant predictors of PCR
positivity in this study; nasal congestion (OR 1.46, [95%CI
0.58–3.57], p ¼ 0.37), fever or chills (OR 1.92, [95%CI
0.80–4.63], p ¼ 0.11) and headaches or myalgia (OR 1.36,
[95%CI 0.57–3.26], p ¼ 0.45).
Bacteria at AECOPD onset
Patients were able to produce spontaneous sputum samples
at the onset of 88 (60%) of AECOPD (Refer Supplementary
Table 1). Bacteria cultured from spontaneous sputum
samples obtained at AECOPD onset of 42 AECOPD (Day 1)
are listed in Table 3. The most common organisms were
Hemophilus influenzae (16) Streptococcus pneumoniae (7)
and Pseudomonas spp. (9). Additional bacterial isolates
obtained at Day 5–7 after AECOPD onset were H. Influenzae
(7), S. pneumoniae (1), Pseudomonas spp. (5) Staphylococ-
cus aureus (2), and other gram negatives (4).
Viral–bacterial co-infection
Eight (19%) of the 42 AECOPD that had a bacterial isolate on
Day 1 also had a virus isolated on respiratory PCR and an
additional four had both viruses and bacteria isolated by
Day 5. The viral–bacterial coinfections were Influenza A and
S. pneumoniae and H. influenzae (1), Picornavirus with
Streptococcus pnuemoniae (3), H. influenzae (4), Pseudo-
monas sp. (2) and Enterobacter sp. (1) and adenovirus with
S. pneumoniae and Acinetobacter sp. (1). Thirty-six percent
of exacerbations in which a virus was detected at onset
developed secondary bacterial infection over the following 7
days. In 30 (71%) of AECOPD in which bacteria were isolated
at onset, the patients had also reported some viral
symptoms at AECOPD onset. Overall 78% of AECOPD in which
H. influenzae was isolated in the first 5 days after onset
were preceded by viral symptoms.
Atypical pneumonia organisms and AECOPD
There were three AECOPD associated with at least a four-
fold rise in atypical pneumonia serology titres; C. pneumo-
niae (1), C. psittaci (1) and Mycoplasma sp. (1) These
exacerbations were associated with a positive viral symptom
score, including symptoms of sore throat, rhinorrhea, fever
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A.F. Hutchinson et al.2478and chills and myalgia. The incidence density of new
infections with atypical organisms was low, at 0.70 per
1000 person-weeks. However, AECOPD associated with
atypical organisms were severe or life threatening and had
a prolonged recovery time.Community acquired pneumonia (CAP)
This study did not exclude AECOPD complicate by CAP. Chest
X-rays were clinically indicated in 26% of AECOPD, (criteria
were; clinical signs of pneumonia, patients attending the
emergency department or requiring inpatient admission).
Review of these chest X-rays showed that six AECOPD were
associated with acute collapse and consolidation. Organisms
identified were Influenza A (1), Moraxella catarrhalis and
Pseudomonas aeruginosa coinfection (1), H. influenzae (1).
No organisms were identified in the other three cases.Clinical severity and inflammatory indices
AECOPD associated with rhinovirus were nine (35%) mild, 15
(58%) moderate and two (7%) severe. AECOPD associated
with RSV and adenovirus were mild, while one parainfluenza
AECOPD was mild, and the other severe complicated by
hypercapnic respiratory failure. The three influenza A
AECOPD were of moderate severity, with the initial infection
resolving within 2 weeks. At 3 weeks, two of these patients
developed mixed viral and bacterial exacerbations that
required inpatient admission.
Serum inflammatory indices were obtained at the onset of
121 (82%) of exacerbations. There was an acute rise in serum
CRP levels at AECOPD onset compared to baseline. Table 4
summarises inflammatory indices according to the labora-
tory confirmed pathogens detected at AECOPD onset. As the
distribution of CRP and ESR values was right skewed, data
was log-transformed prior to further analysis, chi square
tests confirmed that the natural log of these markers was
normally distributed. At AECOPD onset there was an acute
increase in serum CRP levels whether or not a virus was
detected. In PCR positive AECOPD there was a 4.5 fold
increase (geometric mean ratio 4.491 [95%CI: 2.256–8.939],
po0.001) and in PCR negative a 2.7 fold increase (2.709
[95%CI: 1.958–3.747], po0.001).Table 4 Blood inflammatory indices at onset of AECOPD by pa
Viral PCR positive Bacterial
WCC (109/L) 10.9 (4.9–30.1) 12.36 (7.9–19.2)
Neutrophils (109/L) 8.39 (2.1–25.6) 9.7 (3–16.4)
Lymphocytes (109/L) 1.74 (0.5–2.8) 1.3 (0.3–3.3)
Eosinophils (109/L) 0.14 (0–0.6) 0.12 (0–7)
ESR (mm/1 h) 27.9 (9–71) 36.46 (o1–97)
CRP (mg/L) 37.6 (o2–160) 65 (o2–341)
Mean and range of values for each test grouped according to pathog
WCC, white cell count; ESR, erythrocyte sedimentation rate; CRP, CDiscussion
In this study, discordant case-control pairs were 11 times
more likely to have the case positive for viral infection
than the control positive. Only three time-matched
controls were positive for virus. The present study demon-
strates that infection with respiratory viruses, specifically
picornavirus, parainfluenza and influenza, is strongly asso-
ciated with the development of COPD exacerbations
(AECOPD).
The need for rigorous infectious disease epidemiological
study designs that can establish whether or not a novel virus
is pathogenic in humans has been identified as an important
methodological issue.36–40 The strength of this community-
based, case-control study design is time-matching con-
trolled for seasonal fluctuations in viral prevalence. This
presents a solution to the problem of establishing causation
when exposure patterns are random, seasonal or unknown.
The estimated strength of the association between AECOPD
and viral detection will probably change with the preva-
lence, type and virulence of virus circulating in a particular
community. In the present study, the lower limit of the 95%
confidence interval around the odds ratio is greater than
three, establishing that exposure to respiratory viruses
increases the risk of an AECOPD. The use of controls from
within the cohort controlled for both susceptibility to viral
infection and susceptibility to symptoms indicative of an
AECOPD.
To establish that respiratory viruses have a causative role
in triggering exacerbations it is essential to determine
whether viruses are present at the onset of AECOPD.
Previous studies of AECOPD requiring hospitalization
have reported an association, but are not able to establish
whether viral infection precedes the development of
AECOPD.41 This is important because finding a virus in an
established exacerbation (e.g. more than a week old)
may reflect a secondary rather than a primary event.
Basing the study in the community facilitated early
identification of an exacerbation and measurement of
potential triggers shortly after onset. We found that the
majority of viruses were detected in samples obtained
within two days of symptom onset and only a small
number of viruses (five picornaviruses), could still be
detected in exacerbating patients, 5 days after onset of
viral symptoms.thogen identified.
Coinfection No pathogen
identified
Total
10.13 (4.9–16.7) 9.9 (5.9–18) 10.7 (4.9–30.1)
7.48 (2.5–15.6) 7.3 (3–15.2) 8.2 (2.1–25.6)
1.32 (0.8–3.1) 1.5 (0.2–2.9) 1.4 (0.2–3.3)
0.28 (0–1) 0.15 (0–0.5) 0.15 (0–1)
32.11 (o1–65) 33.19 (o1–111) 33.02 (o1–111)
63 (o2–171) 26 (o2–226) 41 (o2–341)
en detection on microbiological tests.
-reactive protein.
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AECOPD, and all but one exacerbating patient had cleared
the virus from the upper respiratory tract by day 30. The
overall detection rates in this study were lower than those
reported in other studies, this may relate to the time
between symptom onset and patient report of symptoms or
the detection technique used or the number of viruses
circulating through our community at that time. The
sensitivity and specificity of respiratory PCR for the
detection of respiratory virus infection is better than
traditional methods using viral culture and serology,
particularly for viruses such as picornavirus.22,42 There
remains some controversy over whether to use nasophar-
yngeal swabs,43 nasal lavage samples44 or induced sputum
samples, for viral detection using PCR techniques. We chose
to use nasopharyngeal swabs, as these are the standard
specimens used by our diagnostic laboratory, are easily
obtained in the community setting, and have the advantage
of capturing virus in the upper respiratory tract shortly after
exposure. In other studies viral detection in nasopharyngeal
swabs is well correlated with infection.22,45 The strength of
the case control methodology is that while some viral
infections may have gone undetected using this technique,
we were still able to establish a strong association between
viral detection and the onset of AECOPD.
In our study picornavirus, RSV and adenovirus were
detected in low numbers in stable COPD. Reported rates of
virus detection in stable COPD vary, with chronic carriage of
RSV, picornavirus and adenovirus identified in different
patient cohorts.11,12,42 The London COPD cohort detected
virus in 39% of stable COPD patients, with RSV accounting for
23% of these.12 In contrast, a recent study found that most
RSV infections were associated with respiratory symptoms
and measurable immune responses and did not find evidence
for persistent RSV infection in stable COPD.45 As it is possible
that viral mRNA may be retained for lengthy periods in
induced sputum, in the absence of active infection this may
also influence the higher detection rate reported in other
studies.
Consistent with recent studies using PCR techniques,
picornavirus was the most common virus associated with
AECOPD in our cohort and was detected throughout the
year.43,46 There were very low levels of influenza infection
detected in the cohort, reflecting low to normal seasonal
influenza activity and that 98% of the cohort was vaccinated
against influenza. Influenza surveillance reports indicate
that in 2003–2005, there was good vaccine coverage for
circulating influenza strains in Australia.47,48 Detection rates
of both picornavirus and parainfluenza increased in syn-
chrony with increased detection of these viruses in the
general community, as reported by influenza surveillance.47
Upper respiratory symptoms of viral infection (rhinorrhoea
and sore throat) were predictive of PCR positivity while
systemic symptoms were not, probably because infection
with viruses such as influenza, that typically cause severe
systemic illness were uncommon.
There was a trend for cohort patients with less severe
disease and better functional capacity to have virus
isolated. Possibly patients with better functional status
were more active in the community, had higher rates of
social contact, resulting in greater exposure to circulating
respiratory viruses. It appears virus exposure rates, ratherthan severe lung function impairment, determined the
likelihood of a viral AECOPD. This finding is supported by
Hurst’s study that found that frequent exacerbations were
associated with more frequent colds, rather than an
increased susceptibility to exacerbate once infected with
a cold.14 It is noteworthy that patients in our study with
repeated viral infections, tended to be those providing
childcare to infants or young children, indicating that
children were one source of repeated exposure to circulat-
ing respiratory viruses. This is consistent with studies that
have found a correlation between the rates of admission for
acute respiratory illness in children and hospital admission
for AECOPD,49,50 and that older adults and children are
usually infected with the same circulating virus strain.51
Laboratory confirmed viral infection preceded the isola-
tion of bacteria in 29% of AECOPD in which bacteria were
isolated in the first five days after exacerbation onset. The
association between influenza virus and bacterial infection
is well documented.52–54 New evidence is emerging that
other respiratory viruses interact with bacteria in the lower
airway in a virus specific, cell-type specific manner.55 Recent
clinical studies indicate that Picornaviridae may interact
with new or colonising bacteria in the lower airway,
resulting in increased bacterial load and heightened
inflammatory responses.14,56 Measuring viral–bacterial in-
teractions was not the primary aim of this study, however we
did observe that confirmed viral infection or probable viral
infection (based on symptoms) preceded 71% of laboratory
confirmed bacterial infections in the first week after
AECOPD onset and 78% of H. influenzae infections. This
highlights the importance of studying the onset of AECOPD in
the community setting, where initial exposures and infec-
tive triggers can be accurately measured. It is clear that
studying hospitalised AECOPD alone will underestimate the
importance of viral infection in triggering AECOPD and the
effect of viral infection on host susceptibility to bacterial
infection. Further research should address the impact of
viral infections on the delicate balance between colonising
bacteria and host immunity
Given the feasibility of reaching patients rapidly after the
onset of AECOPD and the suggestive evidence that that early
therapeutic intervention may reduce burden of disease,57 it
would be highly desirable to accurately and rapidly
differentiate between viral and other causes of AECOPD.
The capacity to identify exacerbations early and differenti-
ate between viral pathogens by PCR, suggests the possibility
of prospective trials of newer antiviral therapies in the
management of AECOPD.58 Community-based studies are
needed to evaluate whether effective early management of
viral exacerbations may decrease the incidence of second-
ary bacterial infection and the overall severity and duration
of the AECOPD episode.
This study demonstrates that the presence of virus in
upper airway secretions is strongly associated with the
development of AECOPD. The strength of the methodologi-
cal approach used in this study is that it controlled for
random and seasonal fluctuations in the levels of virus
circulating in the community. By conducting this study in the
community, we have shown that respiratory viruses can
trigger the onset of AECOPD and that picornaviruses are the
most common viral trigger for AECOPD. These data support
the causative role of viruses in AECOPD.
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